XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 17.15%80.74B | 8.51%21.62B | 49.21%20.09B | 7.68%19.72B | 12.15%19.31B | 2.75%68.92B | 10.14%19.93B | -20.57%13.46B | 12.27%18.32B | 9.53%17.21B |
Operating revenue | 17.15%80.74B | 8.51%21.62B | 49.21%20.09B | 7.68%19.72B | 12.15%19.31B | 2.75%68.92B | 10.14%19.93B | -20.57%13.46B | 12.27%18.32B | 9.53%17.21B |
Cost of revenue | 14.95%65.33B | 9.23%17.39B | 25.92%16.06B | 11.18%16.14B | 15.38%15.74B | 6.41%56.83B | 9.58%15.92B | -5.30%12.75B | 12.93%14.52B | 8.64%13.65B |
Gross profit | 27.47%15.41B | 5.64%4.24B | 464.99%4.03B | -5.72%3.58B | -0.22%3.56B | -11.55%12.09B | 12.39%4.01B | -79.52%714M | 9.80%3.8B | 13.09%3.57B |
Operating expense | 4.03%8.87B | -4.84%2.12B | -4.93%2.01B | 32.42%3.05B | -10.15%1.69B | 4.46%8.53B | 7.51%2.23B | 7.27%2.11B | 9.45%2.3B | -9.34%1.88B |
Selling and administrative expenses | -0.05%5.81B | 8.93%1.57B | -0.86%1.39B | -9.44%1.45B | 2.27%1.39B | 4.23%5.81B | 4.03%1.45B | 3.70%1.4B | 12.36%1.6B | -7.22%1.36B |
Research and development costs | 4.60%2.93B | 6.74%808M | 5.48%751M | -3.16%706M | 10.21%669M | 3.47%2.81B | 5.73%757M | 7.55%712M | 4.44%729M | -4.41%607M |
Other operating expenses | 253.49%132M | -960.00%-258M | -4,366.67%-134M | 3,684.00%896M | -322.73%-372M | 28.33%-86M | 203.45%30M | 93.48%-3M | -47.06%-25M | -214.29%-88M |
Operating profit | 83.60%6.54B | 18.80%2.11B | 245.27%2.03B | -64.57%529M | 10.85%1.87B | -35.30%3.56B | 19.18%1.78B | -191.84%-1.4B | 10.35%1.49B | 56.20%1.69B |
Net non-operating interest income expense | -20.28%-1.87B | 2.01%-487M | -35.22%-503M | -32.11%-469M | -24.32%-409M | -26.26%-1.55B | -57.28%-497M | -17.72%-372M | -15.64%-355M | -13.06%-329M |
Non-operating interest income | 2.00%102M | -50.00%27M | 136.84%45M | 11.76%19M | 10.00%11M | 42.86%100M | 237.50%54M | 90.00%19M | 30.77%17M | -67.74%10M |
Non-operating interest expense | 19.18%1.97B | -6.72%514M | 40.15%548M | 31.18%488M | 23.89%420M | 27.15%1.65B | 65.96%551M | 19.94%391M | 16.25%372M | 5.28%339M |
Other net income (expense) | -16.63%1.52B | -15.38%385M | -14.57%381M | -21.54%368M | -14.85%390M | -0.81%1.83B | -2.15%455M | -5.71%446M | 3.76%469M | 1.10%458M |
Other non- operating income (expenses) | -16.63%1.52B | -15.38%385M | -14.57%381M | -21.54%368M | -14.85%390M | -0.81%1.83B | -2.15%455M | -5.71%446M | 3.76%469M | 1.10%458M |
Income before tax | 61.47%6.19B | 15.79%2.01B | 244.18%1.91B | -73.37%428M | 1.93%1.85B | -37.29%3.84B | 5.79%1.74B | -178.83%-1.32B | 7.28%1.61B | 46.22%1.82B |
Income tax | 158.99%1.18B | 71.37%449M | 195.37%371M | 2.02%253M | -67.76%108M | -42.28%456M | 52.33%262M | -237.94%-389M | 55.00%248M | 188.79%335M |
Net income | 48.31%5.01B | 5.91%1.56B | 264.52%1.54B | -87.12%175M | 17.69%1.74B | -36.32%3.38B | 0.34%1.47B | -166.88%-933M | 1.57%1.36B | 33.79%1.48B |
Net income continuous Operations | 48.31%5.01B | 5.91%1.56B | 264.52%1.54B | -87.12%175M | 17.69%1.74B | -36.55%3.38B | 0.34%1.47B | -166.88%-933M | 1.57%1.36B | 31.53%1.48B |
Net income discontinuous operations | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Minority interest income | 29.19%239M | 65.96%78M | 23.53%63M | 100.00%64M | -38.18%34M | 66.67%185M | 2.17%47M | 537.50%51M | -5.88%32M | 139.13%55M |
Net income attributable to the parent company | 49.42%4.77B | 3.93%1.48B | 249.59%1.47B | -91.64%111M | 19.85%1.71B | -38.52%3.2B | 0.28%1.43B | -170.94%-984M | 1.76%1.33B | 31.55%1.43B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 49.42%4.77B | 3.93%1.48B | 249.59%1.47B | -91.64%111M | 19.85%1.71B | -38.52%3.2B | 0.28%1.43B | -170.94%-984M | 1.76%1.33B | 31.55%1.43B |
Basic earnings per share | 59.82%3.58 | 5.71%1.11 | 261.76%1.1 | -91.21%0.08 | 31.63%1.29 | -36.36%2.24 | 8.25%1.05 | -172.34%-0.68 | 3.41%0.91 | 34.25%0.98 |
Diluted earnings per share | 59.19%3.55 | 4.76%1.1 | 260.29%1.09 | -91.11%0.08 | 31.96%1.28 | -36.29%2.23 | 9.38%1.05 | -172.34%-0.68 | 2.27%0.9 | 34.72%0.97 |
Dividend per share | 6.90%2.48 | 6.78%0.63 | 6.78%0.63 | 6.78%0.63 | 7.27%0.59 | 7.41%2.32 | 7.27%0.59 | 7.27%0.59 | 7.27%0.59 | 7.84%0.55 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |